Related Experiment Video
Updated: May 1, 2026
12:18
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
22.2K
Noncompletion in pediatric rheumatology fellowships
Journal of Graduate Medical Education
|April 5, 2014
Summary
Approximately 16% of pediatric rheumatology fellows did not complete their training. Male fellows, particularly international medical graduates, were more likely to be noncompleters, with rates varying significantly by program.
Area of Science:
- Medical Education
- Pediatric Rheumatology Workforce
- Fellowship Training
Background:
- A shortage of pediatric subspecialists impacts healthcare.
- Fellowship noncompletion's effect on the subspecialty workforce is unknown.
- This study addresses the gap in understanding fellowship noncompletion.
Purpose of the Study:
- Determine the noncompletion rate of pediatric rheumatology fellowships.
- Identify demographic factors associated with fellowship noncompletion.
- Analyze program-specific noncompletion rates.
Main Methods:
- Retrospective cohort study of US pediatric rheumatology trainees (1997-2007).
- Utilized American Board of Pediatrics data to ascertain completion status.
- Compared completers and noncompleters based on sex, medical school location, and age.
Main Results:
- 182 trainees from 28 programs were analyzed; overall noncompletion rate was 16%.
- Male fellows, especially international medical graduates, showed higher noncompletion rates.
- Noncompletion rates varied widely across programs, with no association to program size.
Conclusions:
- One in six pediatric rheumatology fellows did not complete training during the study period.
- Fellowship noncompletion was concentrated in a few programs.
- Further research is needed to understand causes and inform interventions for improving completion rates across specialties.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
01:23Rheumatic Heart Disease I: Introduction
1.0K
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
1.0K
01:26Methods of Documentation II: POMR
1.4K
The Problem-Oriented Medical Record (POMR) revolutionized medical record-keeping by introducing a systematic approach focusing on the patient's problems rather than merely listing symptoms. Dr. Lawrence Weed's introduction of this method in the 1960s marked a significant advancement in medical documentation. The POMR framework consists of four key components: the database, problem list, plan of care, and progress notes.
1.4K
01:21Rheumatic Heart Disease III: Medical Management
544
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
544
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
554
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410